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Jin-Xiong She11, Ashok Sharma11, Andrea Steck5, Jeffrey Krischer2  & The TEDDY Study Group† 
A total of 15 SNPs within complement genes and present on the ImmunoChip were analyzed in The 
Environmental Determinants of Diabetes in the Young (TEDDY) study. A total of 5474 subjects were 
followed from three months of age until islet autoimmunity (IA: n = 413) and the subsequent onset 
of type 1 diabetes (n = 115) for a median of 73 months (IQR 54–91). Three SNPs within ITGAM were 
nominally associated (p < 0.05) with IA: rs1143678 [Hazard ratio; HR 0.80; 95% CI 0.66–0.98; p = 0.032], 
rs1143683 [HR 0.80; 95% CI 0.65–0.98; p = 0.030] and rs4597342 [HR 1.16; 95% CI 1.01–1.32; p = 0.041]. 
When type 1 diabetes was the outcome, in DR3/4 subjects, there was nominal significance for two 
SNPs: rs17615 in CD21 [HR 1.52; 95% CI 1.05–2.20; p = 0.025] and rs4844573 in C4BPA [HR 0.63; 95% 
CI 0.43–0.92; p = 0.017]. Among DR4/4 subjects, rs2230199 in C3 was significantly associated [HR 3.20; 
95% CI 1.75–5.85; p = 0.0002, uncorrected] a significance that withstood Bonferroni correction since it 
was less than 0.000833 (0.05/60) in the HLA-specific analyses. SNPs within the complement genes may 
contribute to IA, the first step to type 1 diabetes, with at least one SNP in C3 significantly associated 
with clinically diagnosed type 1 diabetes.
Currently, autoantibodies are the best markers for screening purposes in large populations of an autoimmune 
attack directed towards the pancreatic islet beta cells. Although the attack is thought to be primarily carried out by 
cytotoxic T cells that recognize autoantigen peptides on beta-cell HLA Class I proteins it cannot be excluded that 
other components of the innate immune system also contributes. Complement factors are proteins involved in the 
innate immune system assisting in opsonizing foreign antigens to increase the immune attack towards bacteria 
and viruses. Other functions of the complement system include chemotaxis where macrophages and neutrophils 
are attracted to the site of infection, cell lysis which is a rupture of foreign cells and agglutination where pathogens 
are clustered together. Complement factors are also linked to the adaptive immune system since antibodies form 
complexes with complements. Genetic variants of genes encoding complement factors have shown associations 
with autoimmune diseases, in particular to type 1 diabetes, systemic lupus erythematosus (SLE) and autoimmune 
macular degeneration (MAD). In type 1 diabetes, studies have shown an increased deposition of C4 in pancre-
ata1, as well as increased levels of plasma protein inhibitor (C1-inhibitor)2. Deposition of C5b-9 (the membrane 
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attack complex (MAC) or terminal complement complex (TCC)) has been identified in neurons of those with 
type 1 diabetes who later died from ketoacidosis3. Increased innate immune reactivity has been detected before 
diabetes-associated seroconversion in children with high-risk HLA genotypes, for example an increased expres-
sion of C2 and C4 binding protein alpha-chain (C4BPA) one to two years prior to diagnosis of type 1 diabetes4. 
Human serum may be toxic to beta-cells by activating the alternative complement pathway5.
Four genes encoding complement proteins (factor B, C2, C4A and C4B) are located on chromosome 6 in the 
human major histocompatibility complex (MHC) that also contains the type 1 diabetes associated HLA-genes. 
The complement genes (CFB, C2, C4A, C4B) are located telomeric between the HLA class II and class I regions. 
Given the extensive linkage disequilibrium in the MHC, these complement genes are inherited as a fixed set 
(a complotype) and have been included in the HLA cluster as an extended HLA haplotype. At least 15 differ-
ent complotypes have been identified with frequency greater than 1% within Caucasian populations6. Certain 
haplotypes within the HLA- complement system are associated with type 1 diabetes, particularly those that 
include HLA-DR3-DQ2. The extended haplotypes of HLA and complement (HLA-A1-B8-BfS- C4AQ0-DR3, 
HLAB18-BfF1-C4A3-C4BQ0-DR3-DQ2 and HLA-A2-CW3-BW62-BfS-C4A3-DR4-DQ8) are increased among 
type 1 diabetes cases compared with controls7. These three haplotypes have been replicated many times as well as 
three additional haplotypes exhibiting association with type 1 diabetes. The B7-BfS-DR2 haplotype has negative 
association with type 1 diabetes (more common in controls than in cases), while five are risk haplotypes of type 1 
diabetes, more common in patients than in controls (B8-BfS-DR3, B8-BfS-DR4, B15-BfS-DR4, B18-BfF1-DR3 
and B40-BfS-DR4)8. Whether these complement gene variants are themselves affecting susceptibility to type 1 
diabetes or are in linkage disequlibrium with other risk contributing genes (including certain HLA class I alleles) 
remains unresolved9–11.
There are three different pathways that activate complement: the classical pathway (immunoglobulin bound 
to antigen), the mannose binding lectin pathway and the alternative pathway. The initial enzyme in the classical 
pathway is C1 (C1q/C1r/C1s). C1q can bind to IgG molecules leading to transactivation of C1q. C1s in turn 
cleaves the proteins C4 and C2 into C4a and C2b. The formation of C4b2a acts as the C3 convertase activating 
enzyme in the classical pathway. The mannose binding lectin pathway (mannose binding to lectin/ficolin bound 
to carbohydrate on pathogen), starts with recognition via mannose-binding lectin (MBL), ficolin 1–3 and CL 11, 
the process continues with involvement of mannose-binding lectin associated serine proteases (MASP-1, MASP-2 
and MASP3) leading to cleavage and activation of C4, C2 and C3. The alternative pathway is initiated by presence 
of pathogen leading to a spontaneous activation of C3. The three pathways results in the formation of C3 conver-
tases that cleave C3 to the C3b and C3a forms. Thereafter C5 is activated and together with C6–9 form the C5b9 
(MAC)12,13. It has been shown that several Ig classes (IgG, IgM and IgA) can be involved in the three pathways13.
Approximately, 50 SNPs within complement genes have been associated with different autoimmune diseases. 
On the ImmunoChip, a custom genotyping array based upon significant genome-wide association with auto-
immune loci with autoimmune diseases, there are 17 complement SNPs that can be interrogated in the TEDDY 
study.
The Environmental Determinants of Diabetes in the Young (TEDDY) is an international prospective study 
of newborn children with an increased genetic risk for type 1 diabetes. Children from the general population 
were enrolled into TEDDY based on their increased genetic risk to type 1 diabetes based upon any of the four 
high-risk HLA-genotypes (DR3/4, DR4/4, DR4/8 or DR3/3). The goal of TEDDY is to identify environmental 
factors that precipitate islet autoimmunity (IA) and subsequent type 1 diabetes in genetically predisposed chil-
dren. Type 1 diabetes develops in at least two phases. A hallmark of the first phase, is an unknown event or agent 
that may trigger the immune system to produce autoantibodies against either insulin, GAD65 or IA-2, alone or 
in combinations as an expression of IA. In this first subclinical phase, there is a shortcoming of insulin produc-
tion. In the second phase, increased blood glucose levels can be detected if an oral glucose tolerance test (OGTT) 
is performed14. This second phase ends with an infiltration of cytotoxic T- cells into the islets of Langerhans’15. 
Persistent confirmed IA, defined as positivity for an autoantibody on two consecutive visits and confirmed in a 
second laboratory, is the primary outcome of TEDDY. The secondary outcome in TEDDY is the diagnosis of type 
1 diabetes as defined by the American Diabetes Association16. It is well documented that the HLA-region contrib-
utes the greatest proportion of genetic risk (~50%) for type 1 diabetes17. Several other genes within the immune 
system also contribute to the genetic susceptibility18,19 in combination with environmental factors.
In the present study, the primary aim was to determine whether SNPs within complement factors were asso-
ciated with IA, or type 1 diabetes, or both, in TEDDY children.
Results
As of 31 December 2014, 7.5% (413/5474) children developed any persistent confirmed IA (M/F = 1.43; 243/170). 
A total of 2.1% (115/5474) of high risk children had progressed to type 1 diabetes (M/F = 1.30; 65/50); how-
ever 5 of the 115 who converted to type 1 diabetes did not have IA. The median follow-up time was 73 months 
(IQR 54–91). The median age at seroconversion to persistent IA was 27.9 (IQR: 15.4–47.8) months and the 
median age at onset of type 1 diabetes was 51.4 (IQR: 29.2–67.5) months. Tables 1 and 2 summarizes demo-
graphic characteristics of the subjects who developed IA and those who developed type 1 diabetes. The three 
HLA-genotypes including DR4 all conferred increased hazard ratios using the time to develop IA as compared 
with DR3/3; DR4/8 [HR = 1.57; 95% CI 1.08–2.28; p = 0.018], DR4/4 [HR = 1.74; 95% CI 1.22–2.47; p = 0.002] 
and in particular DR3/4 [HR = 2.37; 95% CI 1.75–3.22; p < 0.001]. The high-risk genotype HLA-DR3/4 con-
ferred an increased hazard ratio for time to develop type 1 diabetes as compared with DR3/3 [HR = 2.28; 95% CI 
1.30–4.00; p = 0.004].
Hazard ratios using the time to IA in relation to SNPs in complement genes. Proportional hazard 
modeling identified three SNPs as nominally associated (p < 0.05, prior to Bonferroni correction) with IA in the 
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presence of high-risk HLA genotypes in TEDDY participants. Two SNPs in integrin alpha M (ITGAM) were more 
common in controls than cases (protective): rs1143678 [HR = 0.80; 95% CI 0.66–0.98; p = 0.032] and rs1143683 
[HR = 0.80; 95% CI 0.66–0.98; p = 0.030].
SNP rs4597342 in ITGAM was associated with an increased hazard ratio using time to IA [HR = 1.16; 95% CI 
1.01–1.32; p = 0.041] (Table 3).
After Bonferroni correction, none of the 15 SNPs remained as significant.
There was no significant interaction between any of the complement SNPs on IA and HLA- risk categories.
Hazard ratio using time to type 1 diabetes in relation to complement SNPs. None of the 15 SNPs 
tested was associated with time-to-type 1 diabetes in the entire cohort (Table 4).
There were two significant interactions of SNPs with HLA genotype on type 1 diabetes; rs2230199 in C3 
(p = 0.0125) and rs4844573 in C4BPA (p = 0.0275). When the cohort was stratified based on HLA- risk- category, 
three SNPs achieved nominal significance in the time-to-event analysis. Among DR3/4 subjects SNPs: rs17615 in 
CD21 (C3d-receptor) [HR = 1.52; 95% CI 1.05–2.20; p = 0.025: n = 2204] and rs4844573 in C4BPA [HR = 0.63; 
95% CI 0.43–0.92; p = 0.017: n = 2204] reached p < 0.05 (Fig. 1A). Among DR4/4 subjects SNP rs2230199 in C3 
[HR = 3.20; 95% CI 1.75–5.85]; p = 0.0002; n = 1085] achieved Bonferroni-corrected significance since it was less 
than 0.000833 (0.05/60) in the HLA-specific analyses (Fig. 1B). There were no significant associations for any of 
the 15 SNPs with respect to type 1 diabetes among DR4/8 or DR3/3 subjects (Fig. 1C,D).
Subjects who 
developed IA
Subjects who did 
not develop IA
Subjects who 
developed T1D
Subjects who did 
not develop T1D
Number of subjects (n) 413 5061 115 5359
Age at first IA, T1D or the most recent visit (months)
 Median 27.9 69.9 51.4 72.9
 IQR 15.4–47.8 49.7–89.5 29.2–67.5 54.7–91.1
Country n (%)
 Finland 125 (30.3) 1327 (26.2) 41 (35.7) 1411 (26.3)
 Germany 16 (3.9) 235 (4.6) 6 (5.2) 245 (4.6)
 Sweden 159 (38.5) 1746 (34.5) 39 (33.9) 1866 (34.8)
 US 113 (27.3) 1753 (34.7) 29 (25.2) 1837 (34.3)
High-risk HLA-DR-DQ genotype n (%)
 DR3/4 218 (52.8) 1986 (39.2) 65 (56.5) 2139 (39.9)
 DR4/4 78 (18.9) 1008 (19.9) 19 (16.5) 1067 (19.9)
 DR4/8 66 (16.0) 900 (17.8) 16 (13.9) 950 (17.7)
 DR3/3 51 (12.3) 1167 (23.1) 15 (13.1) 1203 (22.5)
Gender n (%)
 Female 170 (41.2) 2487 (49.1) 50 (43.5) 2607 (48.7)
Table 1.  Characteristics of subjects by the status of islet autoimmunity (IA) and type 1 diabetes (T1D) in 
The Environmental Determinants of Diabetes in the Young (TEDDY) study.
IA Type 1 diabetes
HR (95% CI) p HR (95% CI) p
Country (Reference = US)
 Finland 1.31 (1.01–1.69) 0.045 1.61 (0.99–2.62) 0.054
 Germany 1.17 (0.70–1.98) 0.552 1.71 (0.71–4.13) 0.231
 Sweden 1.23 (0.97–1.57) 0.088 1.08 (0.66–1.75) 0.765
High-risk HLA-DR-DQ genotype (Reference = DR3/3)
 DR3/4 2.37 (1.75–3.22) < 0.001 2.28 (1.30–4.00) 0.004
 DR4/4 1.74 (1.22–2.47) 0.002 1.38 (0.70–2.72) 0.353
 DR4/8 1.57 (1.08–2.28) 0.018 1.17 (0.57–2.40) 0.669
Gender (Reference = Male)
 Female 0.72 (0.59–0.87) < 0.001 0.80 (0.56–1.16) 0.243
Table 2.  Adjusted hazard ratios (HR) and p-values from the Cox proportional HR models in the analysis 
of time-to the development of islet autoimmunity (IA) and the analysis of time to the development of type 
1 diabetes respectively. Each of the two models had covariates for country of residence, HLA-DR-DQ genotype 
and gender.
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Discussion
In the present study we were not able to demonstrate a robust association between IA and SNPs within the com-
plement genes. Nevertheless, we found a significant association with type 1 diabetes time-to-event with one SNP 
(rs2230199) in the C3 gene, but only among DR4/4 subjects. There was a strong association for C3 rs2230199 
among HLA-DR4/4 carriers, the genotype conferring the second highest risk for type 1 diabetes. An infection 
could precipitate type 1 diabetes in those with genetic predisposition (based upon rs2230199 in C3) since the 
expression levels of C3 could be different and these subject would not be able to vigorously fight the pathogen. C3 
is a key player in the formation of MAC from all three pathways in the activation of complements.
An infection within the islets of Langerhans’ shortly before the onset of type 1 diabetes could explain the find-
ing of cytotoxic T- cells, which are part of the innate immune response, at the time of diagnosis. The C3 rs2230199 
SNP is a functional polymorphism, where the G allele causes an amino acid substitution where arginine is sub-
stituted with glycine (R102G)20. The glycine variant of C3 moves faster in electrophoresis and has been shown to 
confer increased adhesion to monocytes21. The R102G variant has shown a strong association with age-related 
macular degeneration (AMD)20,22,23. One feature indicating different C3 levels in those with type 1 diabetes is 
that children with type 1 diabetes have impaired clot lysis due to increased incorporation of C3 into clots thereby 
prolonging lysis time24.
There was a strong correlation between the three SNPs in ITGAM (rs1143678 vs rs1143679, rs = 0.85, 
p < 0.0001, rs1143678 vs rs1143683, rs = 0.99, p < 0.0001 and rs1143679 vs rs1143683, rs = 0.85, p < 0.0001) con-
sistent with strong linkage disequilibrium in this region. All three SNPs have previously been shown to impair 
Mac-1-mediated neutrophil phagocytosis and phagocytosis mediated by Fcγ receptors as well as to impair the 
firm adhesion of neutrophils in healthy subjects25. SNP rs17615 in CD21 was associated with an increased haz-
ard ratio using time to type 1 diabetes among HLA-DR3/4 carriers, while those with the rs17615 minor allele 
have been shown to have a protection from SLE. SNP rs17615 (together with rs1048971 and rs4308977) have a 
biological function that decrease the splicing of the alternatively spliced exon 11 conferring increased amounts 
of the short CR2 isoform26. ITGAM, also denoted CD11b-integrin is an adhesion molecule expressed on several 
cells within the innate immune system such as granulocytes, monocytes, macrophages and natural killer cells. 
Moreover, ITGAM is involved in the complement system due to its capacity to bind inactive complement com-
ponent 3b (iC3b)27. One variant within ITGAM (rs1143679, A-allele) confers an amino acid substitution where 
arginine is substituted with histidine R77H. This substitution causes a functional dysfunction of ITGAM lead-
ing to impaired adhesion and reduced phagocytosis of complement opsonized antigens. Interestingly, the R77H 
variant of ITGAM is highly associated with systemic lupus erythematosus (SLE)28. CD21 is also known as the 
C3d-receptor or the Epstein-Barr virus receptor29. The C3d-receptor is expressed on B-cells and has been shown 
Chr SNP
Gene of 
interest
Minor 
allele MAF
HR (95% CI) IA positive 
subjects (n = 413) vs subjects 
with no IA (n = 5061) p
1 rs665691 C1qC G 0.44829 0.98 (0.85–1.12) 0.7450
1 rs17615 CD21 A 0.29459 1.02 (0.88–1.19) 0.7638
1 rs1048971 CD21 A 0.34597 1.02 (0.88–1.18) 0.8277
1 rs4308977 CD21 C 0.29010 1.02 (0.88–1.19) 0.7540
1 rs4844573 C4BPA C 0.37678 0.93 (0.81–1.07) 0.3332
6 rs9332739 C2 C 0.06065 1.04 (0.79–1.38) 0.7733
6 rs2857009 C4 C 0.40608 0.98 (0.82–1.18) 0.8539
9 rs10818488 C5 A 0.45661 1.11 (0.98–1.27) 0.1129
9 rs7029078 C5 G 0.37450 1.03 (0.90–1.18) 0.6711
16 rs1143678 ITGAM T 0.14770 0.80 (0.66–0.98) 0.0324
16 rs1143683 ITGAM T 0.14773 0.80 (0.65–0.98) 0.0301
16 rs1143679 ITGAM A 0.11538 0.82 (0.66–1.01) 0.0667
16 rs4597342 ITGAM T 0.33638 1.16 (1.01–1.32) 0.0406
19 rs2230199 C3 C 0.19865 0.94 (0.79–1.12) 0.4870
19 rs7951 C3 A 0.08916 0.90 (0.70–1.15) 0.3918
Table 3.  Primary statistical analysis of islet autoimmunity (IA). A total of 15 SNPs on the ImmunoChip 
were interrogated in The Environmental Determinants of Diabetes in the Young (TEDDY) study in 413 subjects 
positive for any IA versus 5061 autoantibody negative subjects. Subjects eligible for TEDDY carried any of 
the high risk HLA-DR-DQ genotypes. The minor allele frequency (MAF) was calculated from all subjects 
(n = 5474). Proportional hazard models were adjusted for HLA genotypes, sex and country of residence and 
population stratification. The first two principal components resulting from a principal components analysis of 
the US participants were included in the model to adjust for population stratification. First degree relatives were 
excluded from the analyses. Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated in this 
time-to-event analysis. A robust variance estimate was used to account for the dependence within families in 
the models. The factors indicating nominal significant risk or protection are indicated in bold. For a Chi-square 
value to remain significant after Bonferroni correction for multiple comparisons of 15 SNPs it must be less than 
0.00333. Abbreviations: CD21: C3D-receptor, complement receptor type 2, EBV-receptor ITGAM: Integrin 
alpha M = MAC1 or complement receptor 3, C4BPA: C4 binding protein alpha-chain.
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to increase the B-cell receptor (BCR) signaling as well as to enhance the processing of antigens30. C4BPA has an 
inhibitory effect within the complement system31.
The major strength of the present study is that we have children followed from birth who, in some cases, devel-
oped IA and in some cases progressed to type 1 diabetes, thereby allowing us to study both disease initiation and 
progression. Additional strengths are that we only have included subjects that have high-risk HLA genotypes, 
thereby setting an equal baseline for the major genetic susceptibility. The study design with repeated sampling 
(more often in the toddlers and more dispersed after four years of age) allowed us to use proportional hazard 
ratio modeling to identify hazard ratios for time to end-points (IA and type 1 diabetes) in this cohort consisting 
of three European populations and a USA population (three centers combined). This study design increase the 
power compared with cross-sectional studies of cases and controls. A current limitation on the study, is the 
relatively low number of participants that have reached the end-points (IA and type 1 diabetes). The Bonferroni 
correction might be too conservative if some SNPs are in linkage disequilibrium as is most likely the case for the 
four SNPs within ITGAM, the three SNPs in CD21 the two SNPs in C3 and the two SNPs in C5. Nevertheless, 
among DR4/4 subjects SNP rs2230199 in C3 achieved Bonferroni-corrected significance. As the predisposition 
to type 1 diabetes occurred only in those carrying HLA-DR4/4, the proposed apparent contribution is necessary 
and requires confirmation in functional studies.
As our TEDDY cohort gets older more children will proceed to IA and type 1 diabetes, and we will have more 
power in our determination of association of complement factor gene variants and hazard ratios using time to IA 
and type 1 diabetes.
In summary, although complement gene SNPs are not robustly associated with IA or type 1 diabetes, we 
concluded that variants in the complement genes do have some apparent contribution to IA and type 1 diabetes. 
However, discrimination of complement pathways effects requires further research.
Subjects and Methods
Newborn children were screened for high-risk HLA genotypes and enrolled into the TEDDY study from 1 
September 2004 until 28 February 2010. A total of 424 788 newborns in Finland, Sweden, Germany and the 
United States (Colorado, Georgia and Washington) were screened as previously described32,33. The HLA high- 
risk genotypes for subjects from the general population (GP) were as follows: DR3/4, DR4/4, DR4/8 and DR3/3. 
An additional six genotypes were used for first degree relatives (FDRs) to a subject with type 1 diabetes: DR4/4, 
DR4/1, DR4/13, DR4/4, DR4/9, DR3/9 (Table 5). DR4 subtyping was performed to exclude children from the GP 
with DRB1* 04:03. DQB1* 03:04 also qualified for inclusion into the TEDDY study. Subtyping was not done to 
Chr SNP
Gene of 
interest
Minor 
allele MAF
HR (95% CI) Subjects with 
T1D (n = 115) vs subjects 
without T1D (n = 5359) p
1 rs665691 C1qC G 0.44829 1.10 (0.86–1.41) 0.4540
1 rs17615 CD21 A 0.29459 1.24 (0.94–1.65) 0.1296
1 rs1048971 CD21 A 0.34597 1.14 (0.87–1.50) 0.3333
1 rs4308977 CD21 C 0.29010 1.23 (0.93–1.62) 0.1499
1 rs4844573 C4BPA C 0.37678 0.82 (0.62–1.08) 0.1635
6 rs9332739 C2 C 0.06065 1.08 (0.64–1.80) 0.7848
6 rs2857009 C4 C 0.40608 1.02 (0.73–1.44) 0.8984
9 rs10818488 C5 A 0.45661 1.15 (0.90–1.46) 0.2693
9 rs7029078 C5 G 0.37450 1.12 (0.86–1.47) 0.3954
16 rs1143678 ITGAM T 0.14770 0.84 (0.59–1.20) 0.3447
16 rs1143683 ITGAM T 0.14773 0.84 (0.58–1.20) 0.3363
16 rs1143679 ITGAM A 0.11538 0.66 (0.43–1.04) 0.0709
16 rs4597342 ITGAM T 0.33638 1.05 (0.81–1.37) 0.6935
19 rs2230199 C3 C 0.19865 1.30 (0.95–1.79) 0.1019
19 rs7951 C3 A 0.08916 0.90 (0.56–1.44) 0.6591
Table 4.  Primary statistical analysis of type 1 diabetes. A total of 15 SNPs on the ImmunoChip were 
interrogated in The Environmental Determinants of Diabetes in the Young (TEDDY) study in 115 subjects that 
had developed type 1 diabetes versus all other subjects (n = 5359). Subjects eligible for TEDDY carried any 
of the high risk HLA-DR-DQ genotypes. The minor allele frequency (MAF) was calculated from all subjects 
(n = 5474). Proportional hazard models were adjusted for HLA genotypes, sex and country of residence and 
population stratification. The first two principal components resulting from a principal components analysis of 
the US participants were included in the model to adjust for population stratification. First degree relatives were 
excluded from the analyses. Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated in this 
time-to-event analysis. A robust variance estimate was used to account for the dependence within families in 
the models. For a Chi-square value to remain significant after Bonferroni correction for multiple comparisons 
of 15 SNPs it must be less than 0.00333. Abbreviations: CD21: C3D-receptor, complement receptor type 2, 
EBV-receptor, ITGAM: Integrin alpha M = MAC1 or complement receptor 3, C4BPA: C4 binding protein alpha 
chain.
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distinguish BQB1* 02:0X and DQA1* 03:0X subtypes. In the DQB1* 05:01 haplotype, DR10 had to be excluded, 
only DR1 was eligible. A total of 8667 newborn children were enrolled based on these criteria.
The initial blood sample for HLA- screening was obtained either as cord blood in the maternity clinic or as 
dry blood spot (DBS) on day three to four. If the child carried any of the high- risk genotypes, the family was 
contacted by a study nurse and invited to participate in the 15 year follow-up study with blood sampling for 
analysis of autoantibodies (GADA, IA-2A and mIAA) every 3 months between 3 and 48 months of age and 
every six months thereafter. HLA- genotypes were confirmed in a second blood sample at the 9- month visit. 
This blood sample was also used for the ImmunoChip SNP- analyses. This study was performed according to 
the principles expressed in the Declaration of Helsinki. Signed informed consents were obtained for all study 
participants from their parents or primary caretakers, separately, for genetic screening and participation in the 
follow-up. The study was approved by local Institutional Review Boards and is monitored by an external evalu-
ation committee formed by the National Institutes of Health. The local Institutional Review Boards were as fol-
lows: Colorado Multiple Institutional Review Board (Colorado), Ethics Committee of Southwest Finland Hospital 
District (Finland), University of Florida Health Center Institutional Review Board, Medical College of Georgia 
Human Assurance Committee (2004–2010)/Georgia Health Sciences University Human Assurance Committee 
(2011–2012)/Georgia Regents University Institutional Review Board (2013–present) (Georgia), Bayerischen 
Landesärztekammer Ethics Committee (Germany), Regional Ethics Board in Lund, Section 2 (2004–2012)/Lund 
University Committee for Continuing Ethical Review (2013–present) (Sweden), Washington State Institutional 
Review Board (2004–2012)/Western Institutional Review Board (2013–present) Washington.
Figure 1. The figure illustrates a summary of 15 SNPs within genes in the complement system and present 
on the ImmunoChip that were interrogated in The Environmental Determinants of Diabetes in the Young 
(TEDDY) study in 115 subjects that had developed type 1 diabetes versus all other subjects (n = 5359). 
Subjects eligible for TEDDY carried any of the four high risk HLA-DR-DQ genotypes (DR3/4, 4/4, 4/8 or 3/3). 
The upper 95% confidence interval (CI) is indicated by the upper bar of the box, the lower. 95% CI is indicated 
by the lower bar of the box and the hazard ratio (HR) is indicated by a solid bar in the middle of the box. Three 
hazard ratios were different from 1.0 but only rs2230199 in C3 (p = 0.0002) among the DR4/4 carriers remained 
significant after Bonferroni correction since it was less than 0.000833 (0.05/60) in the HLA specific analyses. 
The explicit values of the HR (95% CI) for type 1 diabetes in the HLA stratified analyses can be found in an 
online Appendix. Panel A HRs and 95% CIs in 65 subjects with type 1 diabetes and 2139 subjects without type 
1 diabetes carrying the HLA-DR3/4-genotype (n = 2204). Panel B HRs and 95% CIs in 19 subjects with type 1 
diabetes and 1067 subjects without type 1 diabetes carrying the HLA DR4/4-genotype (n = 1086). Panel C HRs 
and 95% CIs in 16 subjects with type 1 diabetes and 950 subjects without type 1 diabetes carrying the HLA-
DR4/8-genotype (n = 966). Panel D HRs and 95% CIs in 15 subjects with type 1 diabetes and 1203 subjects 
without type 1 diabetes carrying the HLA- DR3/3- genotype (n = 1218).
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Study outcome – Islet autoimmunity (IA) and type 1 diabetes. The primary outcome was the find-
ing of persistent confirmed IA assessed every 3 months between 3 and 48 months of age and every 6 months 
thereafter. IA was confirmed if identified in both Reference Laboratories. Persistent autoimmunity was defined 
by the finding of confirmed IA (any of GADA, IA-2A or mIAA) on two or more consecutive visits. Date of per-
sistent confirmed IA was defined as the draw date of the first of two consecutive samples of at which the child 
was confirmed as “positive” for a specific autoantibody or any autoantibody. Because children can be born with 
maternal islet autoantibodies, positive results due to maternal transmission via placenta were excluded when 
defining the child’s IA status. In order to discriminate maternal autoantibodies from IA in the child, the IA status 
of the mother was assessed when the child was 9 months if IA was detected at 3 or 6 months of age. The child’s IA 
status was defined based on both maternal and child IA. If maternal autoantibodies were identified, the child was 
not considered persistently IA positive unless the child had a negative sample prior to the first positive sample. 
All samples with a positive result of IA and 5% of negative samples were re-analyzed for confirmation in both 
Reference Laboratories. In the U. S., all samples were assayed at the Barbara Davis Center for Childhood Diabetes 
at the University of Colorado, Denver; in Europe all samples were assayed at the University of Bristol, the U. K. All 
the autoantibodies were measured using radioimmuno-binding assays34–37. The secondary outcome of the study 
was the diagnosis of type 1 diabetes as defined by guidelines from the American Diabetes Association16.
HLA- typing. HLA- genotype screening was performed using either a DBS punch or a small volume whole 
blood lysate (WBL)33,38. Following PCR amplification of exon 2 of the HLA class II gene (DRB1, DQA1 or DQB1), 
alleles were identified either by direct sequencing, oligonucleotide probe hybridization, or other genotyping tech-
niques. Typing to certify specific DR-DQ haplotypes were specified for each clinical center. HLA genotypes in 
eligible subjects were confirmed, using the 9-month sample, by the central HLA Reference Laboratory at Roche 
Molecular Systems, Oakland, CA.
Single Nucleotide Polymorphisms (SNPs). SNP analysis was performed by the Center for Public Health 
Genomics at University of Virginia, using the Illumina ImmunoChip. The ImmunoChip is a custom array for 
genotyping of SNPs selected from regions of the human genome firmly associated with autoimmune diseases. 
The final selection of SNPs containing ~186 000 SNPs in 186 regions, for 12 autoimmune diseases was decided 
by the ImmunoChip Consortium. The 9- month sample was used for SNP genotyping after DNA extraction 
done by Roche Molecular Systems (Pleasanton, CA). Quality control (QC) steps to assure high quality of the 
reported SNPs comprised the exclusion of subjects due to low call rate (> 5% SNPs missing) and discordance 
with reported sex and prior genotyping. Secondly, SNPs were removed from analysis due to low call rate (< 95%), 
Hardy-Weinberg equilibrium (HWE) p-value < 10−6 (except for chromosome 6 due to HLA eligibility require-
ments) as well as being monomorphic or an insertion-deletion.
A total of 17 SNPs residing in loci within genes coding for complement factors were present on the 
ImmunoChip. Of these 17 SNPs, two did not pass QC (rs1061170 in CFH and rs2274567 in CD35). In the TEDDY 
study, we have previously performed a confirmation study of 41 SNPs associated with type 1 diabetes and risk of 
autoantibody positivity39.
Code in 
TEDDY Genotypes Abbreviation
General 
population
A DR3-DQA1* 05:01-DQB1* 02:01/DR4-DQA1* 03:0X-DQB1* 03:02§ DR3/4 Yes
B DR4-DQA1* 03:0X-DQB1* 03:02
§/
DR4-DQA1* 03:0X-DQB1* 03:02§ DR4/4 Yes
C DR4-DQA1* 03:0X-DQB1* 03:02
§/
DR8-DQA1* 04:01-DQB1* 04:02 DR4/8 Yes
D DR3-DQA1* 05:01-DQB1* 02:01/DR3-DQA1* 05:01-DQB1* 02:01 DR3/3 Yes
E DR4-DQA1* 03:0X-DQB1* 03:02
§/
DR4-DQA1* 03:0X-DQB1* 02:01 DR4/4 No
F DR4-DQA1* 03:0X-DQB1* 03:02
§/
DR1#-DQA1* 01:01-DQB1* 05:01 DR4/1 No
G DR4-DQA1* 03:0X-DQB1* 03:02
§/
DR13-DQA1* 01:02-DQB1* 06:04 DR4/13 No
H DR4-DQA1* 03:0X-DQB1* 03:02/DR4-DQA1* 03:01-DQB1* 03:04 DR4/4 No
I DR4-DQA1* 03:0X-DQB1* 03:02
§/
DR9-DQA1* 03:01-DQB1* 03:03 DR4/9 No
J DR3-DQA1* 05:01-DQB1* 02:01/DR9-DQA1* 03:01-DQB1* 03:03 DR3/9 No
Table 5.  Display of high risk HLA-genotypes constituting the criteria for eligibility for first degree relatives 
and children from the general population into The Environmental Determinants of Diabetes in the Young 
(TEDDY). §DR4 subtyping was performed to exclude children from the general population with DRB1* 04:03. 
DQB1* 03:04 also qualified for inclusion into the Environmental Determinants in the Young. Subtyping was not 
done to distinguish DQB1* 02:0X and DQA1* 03:0X subtypes. #In this DQB1* 05:01 haplotype, DR10 had to be 
excluded, only DR1 was eligible. The asterisk (* ) indicate that the alignment is unknown at any point.
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Study population. To allow more generalizable interpretations of the genetic associations, we included 
non-Hispanic Whites from the US sites and all participants from the European sites. Only participants iden-
tified without a type 1 diabetes -FDR were included. After applying these criteria, a total of 5474 participants 
(M/F = 1.06; 2817/2657) with data on 15 SNPs remained in the study.
Statistical analyses. Two outcomes were analyzed: the time to persistent confirmed IA and the time to 
type 1 diabetes. The time to persistent confirmed IA was defined as the age when the first of confirmed positive 
samples was taken, and the right censored time when the last negative sample was taken. The time to type 1 dia-
betes was the child’s age at the time of diagnosis of type 1 diabetes. The primary analysis was to investigate the 
association of the SNPs within the complement genes with the risk of development of persistent confirmed IA/
type 1 diabetes. The minor allele frequency (MAF) was determined in the selected cohort (n = 5474) and used 
throughout the analyses. This strategy infers that the risk is associated with the minor allele, even though the 
certain allele that has the lower frequency may vary across populations. Cox proportional hazard model was used 
for the analyses, adjusting for HLA, sex and country of residence. In addition, the first two principal compo-
nents (PC) of the ImmunoChip data were used as covariates in the Cox model to adjust for potential population 
stratification. The axes of the principal components were estimated based on the TEDDY US Caucasian subjects 
and principle components for all TEDDY Subjects were calculated by projecting their data onto the estimated 
axes. The differences between countries (especially Finland individuals that typically have different PCs) were 
adjusted by the country covariate, and other population substructure (such as northern vs southern European 
of origin) was adjusted by PC1 and PC2. We have re-calculated the data also without correction for the first two 
PCs and the only marked change was that the p-value for rs4597342 in the IA analysis increased from 0.0406 to 
0.0519. Therefore, we present the data with adjustment for the first two PCs throughout this publication. A total 
of 4850 families participated with only one child, 297 families with 2 children, and 10 families with 3 children. A 
robust variance estimate was used to account for the dependence within families in the Cox proportional hazard 
model40.
The secondary analysis was to study the tentative interaction between non-HLA SNPs and HLA-genotype 
and also country-specific association of the SNPs with the time to development of persistent confirmed IA/type 
1 diabetes.
The strength and directions of associations were denoted by hazard ratios (HR) with 95% confidence intervals 
(95% CI). P-values less than 0.05 were considered to indicate nominal statistical significance. Significance after 
Bonferroni correction was achieved when p-values were less than 0.00333 (0.05/15) in the entire cohort and less 
than 0.000833 (0.05/60) in the HLA-specific analyses. Statistical analyses were performed using the Statistical 
Analytical Software (Version 9.3, SAS Institute, Cary, NC). Quality control analyses were performed using PLINK 
(http://pngu.mgh.harvard.edu/purcell/plink)41. The PCA was performed using EIGENSTRAT software42.
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